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Abstract
For the treatment of squamous cell cancer of the head and neck (SCCHN), the assessment of treatment response
is traditionally accomplished by volumetric measurements and has been suggested to be prognostic for an even-
tual response to treatment. An early evaluation response during the course of radiation therapy could provide an
opportunity to tailor treatment to individual patients. Diffusion magnetic resonance imaging (MRI) allows for the
quantification of tissue water diffusion values, thus treatment-induced loss of tumor cells will result in the increase
in water mobility at the microscopic level, which can be detected as an increase in tumor diffusion values before
any volumetric changes occur. We evaluated the use of diffusion MRI as an imaging biomarker of treatment re-
sponse in an orthotopic mouse model of SCCHN. Mice with murine squamous cells expressing the yeast trans-
gene cytosine deaminase were treated with 5-fluorocytosine (5FC), ionizing radiation, and combined therapy and
were compared with control animals both during and after treatment for changes in tumor volumes, diffusion
values, and survival. Radiation therapy had minimal effect on volumetric growth rate, diffusion, or survival. Al-
though 5FC and combination treatment resulted in similar reductions in tumor volumes, the combination treat-
ment elicited a much greater increase in tumor diffusion values, which correlated with improved survival. Thus,
diffusion MRI as an imaging biomarker has a potential for early evaluation of the response to chemoradiation treat-
ment in SCCHN.
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Introduction
There will be an estimated 47,000 cancers of the mouth, tongue,
pharynx, and larynx in the United States in 2008 with approximately
11,000 deaths [1]. As such, squamous cell cancer of the head and
neck (SCCHN) will makeup 2.5% of all cancers and 1% of all
deaths caused by cancer during this period. Greater than 90% of
these cases are composed of the common histologic diagnosis, squa-
mous cell carcinoma. Surgery remains the mainstay of treatment in
head and neck cancer; however, more than 60% of all SCCHN are
present in a locally advanced stage where surgery alone is no longer
considered curative. Therefore, the combination of chemotherapy
and radiation therapy either adjuvantly after maximal surgical resec-
tion or as definitive treatment has become the standard of care for
many patients [2].
Chemotherapy alone has an excellent response rate in SCCHN
with up to 80% overall response and complete response (CR) rates
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in the range of 25% when using multiagent induction chemotherapy
[3]. However, despite these excellent response rates, there is little ev-
idence for a survival benefit with induction chemotherapy followed
by either surgery or definitive radiation therapy, although a recent
meta-analysis did reveal a small survival benefit to induction chemo-
therapy before radiotherapy [4]. In contrast, the addition of concur-
rent chemotherapy to radiation therapy (most typically platinum
based chemotherapy) has proven to provide a significant benefit in
terms of local control and overall survival in both definitive and ad-
juvant radiation therapies in the treatment of locally advanced
SCCHN [2–4].
Typically, evaluation of response to therapy in head and neck can-
cer has been through physical examination, evaluation in the operat-
ing suite through direct laryngoscopy, and by cross-sectional imaging
[computed tomography (CT) or magnetic resonance imaging (MRI)]
[3]. An early evaluation of tumor response may provide prognostic
information about treatment efficacy and allow subsequent tailoring
of interventions based upon individual response such as using image-
guided adaptive radiotherapy [5]. Computed tomography has been
evaluated as a noninvasive means for evaluating the response of in-
duction chemoradiotherapy before surgical resection for SCCHN.
However, in this case, strictly volumetric response based on CT ex-
aminations gave both poor positive and negative predictive values
when compared to histologic finding obtained at resection [6]. Com-
puted tomographic examinations have also been used to evaluate re-
sponse to radiation therapy both during treatment and 8 to 10 weeks
after the completion of treatment [7–11]. Some authors have sug-
gested that rapid response during radiation therapy was a positive
predictor of eventual tumor control [11], whereas others have found
that a more protracted response was a better prognostic factor [7].
Thus, the use of volumetric-based measurements especially during
radiation treatment is unclear at this time, although the combined
use of CT and endoscopic evaluation has been suggested to predict
for a good response to chemotherapy and a greater likelihood of organ
preservation in head and neck cancer of the larynx, hypopharynx, and
oropharynx [12–16].
Functional imaging–based assessments have also been assessed re-
cently. Positron emission tomography using 18F-fluoro-deoxy-glucose
(FDG-PET) has been proven to predict for response to chemo-
radiotherapy in patients with head and neck cancer when measured
several months after treatment [17,18]. In addition, a negative FDG-
PET scan has been demonstrated to predict response in cervical
lymph node metastases of head and neck cancer, therefore eliminat-
ing the need for post treatment neck dissection in patients who
achieve a CR by FDG-PET [17]. However, currently, there is limited
evidence for the use of PET during radiotherapy, and indeed, there is
concern that acute inflammation caused by radiation of mucosal tis-
sues could lead to false-positive determinations using FDG-PET
[19]. Dynamic contrast-enhanced MRI [20] or other perfusion-based
techniques [21] are alternative imaging modalities, which have been
evaluated as early markers of response in head and neck cancer.
An imaging approach that is rapidly gaining interest for the detec-
tion of cancer treatment response is diffusion MRI [22] (Figure 1).
Diffusion MRI is sensitive to the subcellular motion of water in bi-
ologic tissues and has been demonstrated to be effective both in di-
agnosing head and neck cancers [23] and in detecting relapses many
months after the completion of radiation therapy [24]. However, the
use of diffusion MRI during treatment of head and neck cancer has
not been appropriately evaluated. Diffusion MRI early in a course of
treatment would allow for the detection of alterations in tumor cell
membrane integrity (i.e., microenvironment) after a therapeutic in-
tervention using the Brownian motion of water (e.g., water diffusion)
as a surrogate. This is accomplished based on the use of diffusion
MRI pulse sequences allowing for collection of multislice image data
sets wherein the magnetic resonance signal intensity is dependent on
the mobility of the water molecules within the tissue [25]. At the
start of treatment, tumors are anticipated to be densely cellular with
a diffusion histogram reflective of this (Figure 1, top panel ). Shortly
after initiation of an effective treatment, there is initial breakdown of
cellular membranes, which is detectable as a shift in the diffusion
histogram to the right to more closely approximate an environment
with increased water mobility, and this increase in water diffusion
precedes overt volumetric changes in tumor size (Figure 1, middle
panel ). Finally, after the completion of an effective treatment, frank
tumor death (necrotic or apoptotic) leads to further breakdown of
cells and broadening of the diffusion histogram and often with a co-
incident decrease in tumor volume (Figure 1, bottom panel ).
The initial application of diffusion MRI for the detection of tumor
treatment response was reported using a rodent glioma model [26].
Further validation studies have expanded significantly on these initial
results using a variety of tumor models and therapeutic agents [27–
31]. Overall, these studies have shown that diffusion MRI can serve
as a sensitive imaging biomarker for the detection of early cellular
changes in treated tumors, which precede macroscopic volumetric
response. Moreover, diffusion MRI measurements can be used to
identify spatially distinct regional responses to therapy in tumors
[31–35]. Translation of diffusion MRI into brain tumor clinical trials
has been accomplished [33,34,36] where changes in diffusion mea-
sures have recently been shown to be strongly correlated both with
overall clinical response based on the World Health Organization re-
sponse criteria [34,36] and with overall survival [33]. In addition,
preliminary data would also support diffusion MRI as an early re-
sponse metric to combined chemoradiotherapy in head and neck
cancer [37,38]. Thus, diffusion MRI is emerging as an important
predictive biomarker for early stratification of tumor response.
The purpose of the current study was to evaluate whether diffusion
MRI could be extended to assess treatment effects in SCCHN. The
murine SCCVII squamous tumor model was used with cells genet-
ically engineered to express a therapeutic transgene [yeast cytosine de-
aminase (yCD)], which, when exposed to a prodrug, 5-fluorocytosine
(5FC), generates high concentrations of the chemotherapeutic agent
5-fluorouracil (5FU) locally within the tumor [39]. Treatment effects
on diffusion were evaluated after treatment with radiation and radio-
chemotherapy and revealed that SCCVII tumor diffusion changes
were correlated with treatment outcome measures (tumor burden
and survival) better than conventional radiographic response, suggest-
ing that further translational clinical studies are warranted.
Materials and Methods
Orthotopic Tumor Implantation
All of the animal work was carried out in the animal facility at
the University of Michigan in accordance with federal, local, and in-
stitutional guidelines. Briefly, a yCD-expressing murine squamous
SCCVII stable cell line was established by retroviral infection and
limiting dilution in 96-well plates as previously reported [39]. These
SCCVII cells (grown in medium culture) were trypsinized, washed
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in phosphate-buffered saline (PBS), counted, and resuspended at a
concentration of 4 × 108 cells/ml in PBS. Fifty microliters of this
cell solution was injected into the submental compartment of C3H
mice (6-8 weeks; Charles River Laboratories, Wilmington, MA) along
the midline, using an external approach [39–41]. Mice were weighed
every 2 to 3 days and were euthanized if they exceeded a body weight
loss of >25%. For all studies, animals were anesthetized with an air/
isoflurane (1.25%) mixture.
Chemotherapy and Radiation Treatment
Twenty-four animals with SCCVII tumors were entered into the
study. Treatment was delivered as previously described [41]. When
in vivo tumor volumes reached 15 to 20 μl, animals were divided
into four groups. Group 1 was designated as the control group that
received 0.1 ml of drug vehicle (10% ethanol in PBS daily by i.p.
injection; n = 6). Groups 2, 3, and 4 received 5FC (n = 6), radiation
(n = 6), and 5FC plus radiation (n = 6), respectively. All 5FC treat-
ments (500 mg/kg daily) were administered by a single i.p. injection
on days 0 to 4. Groups 3 and 4 animals received five doses of ion-
izing radiation at 4 Gy/day delivered on days 0 to 4. T2-weighted
and diffusion MRI was performed every other day (n = 3 per imaging
group) to measure volumetric and tumor water diffusion changes,
respectively. Animal survival data were also obtained for all animals.
Magnetic Resonance Imaging
Tumors were imaged over a 3 week time frame using a Varian Unity
Inova MRI system (Varian Instruments, Fremont, CA) equipped with
a 7-T, 18.3-cm horizontal bore magnet (Oxford Instruments, Oxford,
UK). During all MRI procedures, animals were anesthetized using
1.25% isoflurane, and body temperature was maintained at 37°C
using a heated water recirculating pad. For anatomical imaging, a
“fast spin-echo multislice” MRI sequence (TR/TE = 4000/60 millisec-
onds, number of transitients = 4, number of echoes = 8, FOV = 30 ×
30 mm, image matrix = 128 × 128, slice thickness = 1 mm) was used
to collect 13 contiguous T2-weighted images.
Maps of tumor apparent diffusion coefficient (ADC) values were ac-
quired using a recently described method [31]. Briefly, a trace diffusion-
weighted multislice spin-echo sequence (with motion compensation
Figure 1. Schematic representation of diffusion MRI measured response to therapy. Changes in tumor cellularity (left) and increased
molecular water mobility measured as the ADC (right) as a tumor responds to treatment (top to bottom). For a tumor responding to
therapy, an increase in extracellular space/membrane permeability would be anticipated to increase both water mobility and ADC.
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and a navigator echo) was used to acquire 13 slices with two different
diffusion weightings (b1 = 100 and b2 = 1248 sec/mm
2). The image
slice thickness was 1 mm, image matrix was 128 × 128 (zero filled to
256), field of view was 30 × 30 mm, and echo time was 60 millisec-
onds. The images acquired with b1 were essentially T2-weighted
images, and these were used to segment the tumor from nontumor
tissue for volumetric analysis using an “in-house” region drawing tool
developed in Matlab.
Statistical Analysis
A 2-tailed t test was used to compare volume and diffusion data
between groups. For comparison of animal overall survival, a log rank
test was performed. Statistical analysis was performed using MedCalc
(MedCalc, Version 9.5.1, Mariakerke, Belgium) with P < .05 consid-
ered to be statistically significant.
Results
Development of Orthotopic Model of
Concurrent Chemoradiotherapy
In this study, we used an orthotopic model of SCCHN, which was
previously demonstrated to mimic the locally invasive nature of this
disease [39–41]. Murine squamous cells (SCCVII) were injected sub-
mentally forming a locally infiltrative tumor with near 100% tumor
take. Tumors were allowed to grow sufficiently to have measurable
dimensions for MRI-based imaging (15-20 μl at 3 days after implan-
tation; Figure 2). As previously reported, we found that radiation
therapy alone (4 Gy × 5 daily fractions) had limited efficacy in this
model given the rapid growth of the tumor and the constraints on
radiation dose caused by adjacent normal mucosa [41]. Combined
chemoradiotherapy in this model using conventional agents (cisplatin,
5FU, or gemcitabine) was also found to be problematic owing to the
abrupt and abundant mucositis and corresponding weight loss that
developed. We initially tested the above three chemoradiotherapy
regimens in non–tumor-bearing mice with radiation administered
to the oral mucosa, and median weight loss within the first 2 weeks
was >25% with a significant number of animals requiring euthanasia
secondary to treatment toxicity (data not shown). We thus engen-
dered to find an alternative model for concurrent chemoradiotherapy,
which would limit the acute mucosal reactions and morbidity and
allow evaluation of early MRI markers of treatment response [39,41].
Previously, we have reported on the use of genetically modified cells
stably expressing either bacterial [41] or yeast cytosine deaminase
[39], which allow the local conversion of 5FC, a nontoxic prodrug,
to 5FU, a commonly used chemotherapeutic and radiosensitizing
agent. Use of this gene therapy strategy was tolerable in this orthotopic
model either alone or when combined with fractionated external beam
radiotherapy [39,41]. Therefore, to serve as a model for concurrent
chemoradiotherapy, orthotopic tumors that expressed yeast cytosine
deaminase were developed, which were then treated with systemic
5FC either with or without fractionated external beam radiotherapy.
After implantation, tumors expressing yCD readily grew within the
submental compartment with a tumor-doubling time (4.1 ± 0.8 days)
that was indistinguishable fromwild type SCCVII cells [40,41] (P > .1;
Figures 2A and 3).
Concurrent Chemoradiotherapy Does Not Increase the Rate of
Response in Head and Neck Tumors
To test the use of radiation therapy either alone or when combined
with systemically administered 5FC in yCD-expressing tumors in the
submental compartment, animals were separated into four treatment
groups. Control animals received a daily i.p. injection of carrier so-
lution for 5 days. Radiation-treated animals were treated with 4 Gy
daily for five consecutive days. Chemotherapy-treated animals re-
ceived five consecutive daily i.p. injections of 5FC (500 mg/kg). Fi-
nally, combined modality–treated animals received both daily 5FC
for 5 days along with five fractions of radiation (4 Gy each) delivered
Figure 2. Submental tumor growth. Sequential T2-weighted MRI images of a slice through a control (A), a 5FC-treated (B), and a 5FC and
radiation–treated (C) yCD-expressing SCCVII tumor. Images were acquired 1 day before therapy and 1, 3, 5, and 7 days after therapy. The
submental tumors are indicated by the red, blue, and green regions of interest, respectively.
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concurrent with chemotherapy treatment. A total of six animals were
treated in each group for toxicity and survival analysis, and at the
start of the study, three animals from each group were randomly se-
lected for sequential imaging with MRI.
Figure 2 displays sequential representative T2-weighted MRI slices
from one animal from each group, whereas Figure 3 displays the
overall tumor growth curve. The maximum tumor diameter is de-
picted at each time point on the images, although all measures of
response were based on volumetric analysis across all MRI slices.
These diffusion-weighted images are essentially heavily T2-weighted
with areas of increasing diffusion depicted as a higher intensity signal.
As can be seen in Figure 2 A, control animals had tumors that grew
rapidly after implantation with a locally invasive and exophytic tu-
mor developing within the submental compartment. These tumors
were also relatively solid with an ADC, which approximated that
of surrounding muscle (Figure 2A); however, during the first week,
as untreated tumors grew (Figure 3), they become more solid and
cellular with a decrease in the ADC (Figure 4). Treatment with frac-
tionated radiation therapy alone had only limited impact on tumor
growth (Figure 3) that was not significantly different from control
animals. In addition, the diffusion characteristics of these tumors ap-
proximated surrounding soft tissues with no significant increase in
diffusion signal (Figure 4). In animals treated with systemic 5FC
(Figure 2B), there was a marked arrest of tumor growth within 3 days
after treatment, with a complete regression of tumor witnessed by
day 7 of treatment; however, there was no significant increase in
diffusion signal within the tumors during this period of tumor regres-
sion (Figure 2B). Finally, in animals treated with combination ther-
apy (Figure 2C ), there was also a significant regression of tumor
leading to a CR by day 7 after treatment, which paralleled the
5FC-treated animals in the rate and extent of response (Figure 3).
However, unlike the 5FC-treated animals, there was a substantial rise
in the ADC of the submental tumors as witnessed by the greatly in-
creased signal within the tumor (Figure 2C ).
A comparison of the rate of tumor growth across all animals re-
vealed a near constant growth of control tumors reaching a volume
more than threefold larger than the starting size 9 days after the start
of treatment (and 12 days after implantation; Figure 3, open squares).
In animals treated with daily fractionated radiation, there was only
limited growth delay that was not statistically significant when com-
pared with control tumors (Figure 3, closed squares). In contrast,
treatment with daily 5FC (Figure 3, open circles) resulted in rapid
tumor shrinkage such that no measurable tumor was identifiable as
early as 9 days after the start of treatment. Finally, in animals treated
with combination therapy (Figure 3, closed circles), there was also an
abrupt shrinkage of tumor resulting in a radiographic CR by 9 days
after treatment. The rates of tumor regression in 5FC- or combination-
treated animals were both statistically different from the control–
and radiation-treated groups from day 3 of treatment onward (all
P values in pairwise comparison <.04). In contrast, there was no signif-
icant difference between the growth rates of control- and radiation-
treated animals (P > .1) or between the 5FC or combination therapy
groups (P > .1).
Diffusion MRI Predicts Enhanced Response to
Combined Therapy
Unlike the volumetric measures, which could not distinguish be-
tween the two treatment groups involving chemotherapy, when the
mean ADC in the tumor masses were calculated, it was apparent that
the combination therapy animals were exhibiting a much more
abrupt rise in ADC (Figure 4, closed circles), which was different from
the other three groups by 5 days after treatment and this difference
continued to increase. The area under the curve of the change in the
ADC as a function of time for combination therapy was statistically
different from all other treatment groups (P < .03, P < .04, and P <
.05, respectively, when compared with control-, radiation-, and 5FC-
treated groups). In contrast, there was no significant difference be-
tween the remaining treatment groups; although there was a trend
toward a greater area under the curve for 5FC-treated animals when
compared with radiation-treated or control animals (P < .08).
Combined Modality Therapy Led to Enhanced Tumor Control
Overall tumor control and animal survival were evaluated, and
there was no significant difference in tumor control or median sur-
vival between control- and radiation-treated groups (Figure 5). There
was a trend toward a slightly increased median survival time in ani-
mals treated with radiation when compared with controls (33 vs
28 days); however, this difference did not achieve statistical signifi-
cance (P > .1). In contrast, in animals treated with daily 5FC, there
Figure 3. In vivo orthotopic tumor growth. Relative tumor volumes
(±SEM; as measured on T2-weighted MRI) as a function of time
after therapy for control-, 5FC-, 5FC and radiation–, and radiation-
treated yCD-expressing SCCVII tumors.
Figure 4. In vivo orthotopic tumor ADC changes. Mean ADC val-
ues (±SEM; as measured diffusion-weighted MRI) as a function
of time after therapy for control-, 5FC-, 5FC and radiation–, and
radiation-treated yCD-expressing SCCVII tumors.
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was improved tumor control, with two of six animals free of tumor
90 days after tumor implantation and a median survival of 66 days
that was statistically different from both control- and radiation-treated
animals (P < .0006 for each). Finally, in the combination therapy
group of animals, a greatly enhanced tumor control was observed
when compared to all other groups, with five of six animals free
of tumor 90 days after implantation and the median survival time
that was not reached. Survival in the combination treatment group
was statistically improved when compared not only to control- or
radiation-treated animals (P < .0006 for each) but also to those ani-
mals treated with 5FC only (P < .05). At the time of death of all
animals in each of these four groups, there was a grossly identifiable
tumor within the submental compartment at postmortem analysis.
In contrast, at the end of the experiment (90 days after implanta-
tion), there was no radiographically or grossly identifiable disease
in any of the seven animals left alive in the 5FC or combination ther-
apy groups.
Discussion
Treatment of head and neck cancer once the province of surgical
resection alone is becoming more and more a multimodality disease
[2,3]. However, the best way to integrate these different modalities is
still not completely clear. Each of the commonly used treatments
(surgery, radiation therapy, and chemotherapy) has its own unique
benefits and toxicities. The goal of multimodality therapy is to judi-
ciously use each of these treatments in a manner that maximizes ben-
efit while limiting toxicity. The goal of early assessments of treatment
response would be to allow an early and accurate evaluation of treat-
ment efficacy, which would enable treatments to be tailored between
individual patients instead of simply applying a treatment based on
population norms or historical treatment information.
Standard volumetric-based assessments of treatment response in
patients with head and neck cancer after induction chemotherapy
have enabled selection of patients who are likely to benefit from sub-
sequent radiotherapy or chemoradiotherapy [12–14,16]. However,
these regimens have often entailed as many as three cycles of chemo-
therapy delivered for 9 or more weeks, which greatly increased the
time and morbidity of treatment without providing any improve-
ment in patient survival [12–14]. The use of volumetric measures
during or shortly after radiotherapy has been difficult and has been
found to only poorly correlate with eventual pathologic tumor con-
trol. In contrast, response as assessed by CT scan or PETmany weeks
to months after radiotherapy does have prognostic information regard-
ing tumor control but is hampered by the long time after treatment to
assess the response and would not allow adaptive radiotherapy based
on intratreatment assessment of response.
In the current study, we tested a novel imaging technique to com-
pare the differences in diffusion-weighted imaging within a tumor
mass in response to treatment as a metric for eventual tumor control.
The model system used incorporated a rapidly growing SCCHN line
that is only minimally responsive to radiotherapy as revealed by both
standard MRI [41] and diffusion MRI. Either chemotherapy, using a
novel enzyme/prodrug gene therapy system, or the combination of
chemotherapy and radiotherapy gave excellent response with com-
plete regression of tumor observed in all animals. Despite complete
radiographic response to single-agent chemotherapy, four of six ani-
mals eventually recurred with large submental tumors. Supporting
our earlier work with this system [39,41], the combination of radio-
therapy and chemotherapy did result in increased tumor control and
enhanced animal survival compared with either chemotherapy or
radiotherapy alone with five of six animals alive and free of disease
90 days after tumor implantation.
Diffusion MRI has previously been demonstrated to correlate with
cellular density in rodent models of glioma and breast cancer [42–
44]. In addition, changes in diffusion-weighted imaging have been
proposed as a marker for early treatment response in both animal
models of glioma [35,43] and in patients receiving chemotherapy
or radiotherapy for primary brain tumors [33,34,36,45,46]. In pa-
tients with primary central nervous system malignancies, the com-
bination of diffusion-weighted imaging both before and 3 weeks
after the start of treatment has been demonstrated to predict eventual
radiographic response at 10 weeks with both high sensitivity and
specificity [36]. In addition, in a subset of patients with high-grade
malignant glioma, diffusion-weighted imaging obtained as early as
3 weeks after the start of a course of fractionated radiation therapy
predicted not only radiographic response but also time to progression
and overall survival [33,34]. In our studies of glioma, we have found
that a regional evaluation of diffusion response was more predictive
of survival than simple measurements in the increase in overall aver-
age ADC [33–36]; however, in this animal model, given the very
small size of tumors and their rapid growth rate, this regional eval-
uation was not feasible. Therefore, it is possible that, with further
technologic application, this regional evaluation of diffusion response
will be even more predictive of later clinical outcome.
One further potential advantage demonstrated in this study, which
needs to be explored, is the fact that, even with CR to therapy, 5 of
12 animals eventually recurred (4/6 in the 5FC group and 1/6 in the
5FC + radiation group). In contrast, the much greater rise in ADC
observed in the combined modality group only 3 days into treatment
correlated with a significantly greater tumor control. We previously
observed this phenomenon in a rodent glioma tumor model as well
where radiographic CR to treatment was poorly correlated with tu-
mor control, whereas a radiographic CR in the setting of a threefold
rise in tumor ADC predicted for long-term tumor control [47]. The
lack of a CR to chemotherapy correlating with significant clinical ad-
vantage would also be supported by the extensive experience with
Figure 5. Overall animal survival with in vivo orthotopic tumors.
Relative survival probability as a function of time after implantation
for control-, 5FC-, 5FC and radiation–, and radiation-treated yCD-
expressing SCCVII tumors.
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induction chemotherapy in head and neck cancer where as many as
30% to 40% of patients could be rendered radiographically free of
disease before radiotherapy with only a very modest improvement in
survival [4]. In contrast, a more intensive therapy with concurrent
chemotherapy and radiation therapy has been associated with a sig-
nificantly greater survival advantage [4].
Thus, in preclinical and clinical evaluation of head and neck can-
cer, a rapid CR to chemotherapy did not predict for ultimate tumor
control. However, the preclinical data presented here for diffusion
MRI suggest that this technique may be able to differentiate between
those radiographic responses that are more likely to be durable. Ini-
tial experience with diffusion MRI in head and neck cancer supports
this technique as technically achievable in patients with head and
neck cancer being treated with concurrent chemoradiotherapy. In
two pilot studies, significant increases in tumor ADC were observed
as early as 1 [38] to 2 weeks [37] into chemoradiotherapy that seem
to predict subsequent radiographic response. It remains to be seen if
further evaluation of diffusion MRI as an early biomarker of response
will enable patient-specific tailoring of chemotherapy and radiation
therapy in patients with head and neck cancer to maintain tumor
control while decreasing the overall toxicity of treatment and increas-
ing patient quality of life.
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